Abstract:The drug resistance in cancer treatment with DOX is mainly related to the overexpression of drug efflux proteins, residing in the plasma and nuclear membranes. Delivering DOX into the mitochondria, lacking drug efflux proteins, is an interesting method to overcome DOX resistance. To solve the problem of positively charged triphenylphosphonium (TPP) for mitochondrial targeting in vivo, a charge reversal strategy was developed. Methods: An acidity triggered cleavable polyanion PEI-DMMA (PD) was coated on the surface of positively charged lipid-polymer hybrid nanoparticle (DOX-PLGA/CPT) to form DOX-PLGA/CPT/PD via electrostatic interaction. The mitochondrial localization and anticancer efficacy of DOX-PLGA/CPT/PD was evaluated both in vitro and in vivo. Results: The surface negative charge of DOX-PLGA/CPT/PD prevents from rapid clearance in the blood and improved the accumulation in tumor tissue through the enhanced permeability and retention (EPR) effect. The hydrolysis of amide bonds in PD in weakly acidic tumor tissue leads to the conversion of DOX-PLGA/CPT/PD to DOX-PLGA/CPT. The positive charge of DOX-PLGA/CPT enhances the interaction with tumor cells, promotes the uptake and improves DOX contents in tumor cells. Once endocytosed by tumor cells, the exposed TPP in nanomedicine results in effective mitochondrial localization of DOX-PLGA/CPT. Afterward, DOX can release from the nanomedicine in the mitochondria, target mtDNA, induce tumor cells apoptosis and overcome DOX resistance of MCF-7/ADR breast cancer. Conclusion: Tumor acidity triggered charge reversal of TPP-containing nanomedicine and activation of mitochondrial targeting is a simple and effective strategy for the delivery of DOX into the mitochondria of cancer cells and overcoming DOX resistance of MCF-7/ADR tumor both in vitro and in vivo, providing new insight in the design of nanomedicines for cancer chemotherapy.

Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance.

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Mitochondria and Nucleus Dual Delivery System to Overcome DOX Resistance

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance

Dual Aptamer Modified Dendrigraft Poly-L-lysine Nanoparticles for Overcoming Multi-Drug Resistance Through Mitochondrial Targeting.

Amphiphilic tumor-targeting chimeric peptide-based drug self-delivery nanomicelles for overcoming drug resistance in cancer by synergistic chemo-photodynamic therapy

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

Overcoming Chemotherapy Resistance Via Simultaneous Drug-Efflux Circumvention and Mitochondrial Targeting

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

Polyplexes by Polymerized Dequalinium and Bifunctional Aptamer for Mitochondrial Targeting Drug Release to Overcome Drug Resistance

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Dextran-based Nanodrugs with Mitochondrial Targeting/glutathione Depleting Synergy for Enhanced Photodynamic Therapy

Long-Circulating Amphiphilic Doxorubicin For Tumor Mitochondria-Specific Targeting

Overcoming Drug Resistance with Functional Mesoporous Titanium Dioxide Nanoparticles Combining Targeting, Drug Delivery and Photodynamic Therapy

Mitochondria-targeted Vitamin E Succinate Delivery for Reversal of Multidrug Resistance

Reversal of Doxorubicin Resistance in Breast Cancer by Mitochondria-Targeted Ph-Responsive Micelles.

Tumor-Penetrating and Mitochondria-Targeted Drug Delivery Overcomes Doxorubicin Resistance in Lung Cancer

A TRACKABLE DRUG DELIVERY CARRIER MODIFIED WITH MITOCHONDRIAL TARGETING CONJUGATE FOR OVERCOMING DRUG RESISTANCE

Stepwise Dual Targeting and Dual Responsive Polymer Micelles for Mitochondrion Therapy.

Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anti-cancer Drug to Overcome Tumor Multidrug Resistance.

Mitochondrion-specific Dendritic Lipopeptide Liposomes for Targeted Sub-Cellular Delivery